# \[e-drug\] Two UNDP publications - India and patents

**URL:** <https://talk.edrugplus.org/t/e-drug-two-undp-publications-india-and-patents/35021>\
**Category:** e-drug\
**Created:** [February 2, 2011, 12:44am UTC](https://talk.edrugplus.org/t/e-drug-two-undp-publications-india-and-patents/35021 "2011-02-02T00:44:01Z")\
**Posts on this page:** 1\
**Page:** 1

<div class="post-metadata">

**Author:** ![Tenu\_Avafia](https://avatars.discourse-cdn.com/v4/letter/t/f475e1/32.png) [@Tenu\_Avafia](https://talk.edrugplus.org/u/Tenu_Avafia)\
**Post date:** [February 2, 2011, 12:44am UTC](https://talk.edrugplus.org/t/e-drug-two-undp-publications-india-and-patents/35021/1 "2011-02-02T00:44:01Z")

</div>

E-Drug: Two UNDP publications - India and patents  
-------------------------------------------------

[Please add name, affiliation and e-mail address to messages - DB]

Dear E-druggers

You may find the following two reports on intellectual property rights issues of interest:

1. The report entitled “Five years into the product patent regime: India’s  
response“ is intended to be a contribution towards understanding the  
continued role of India as a supplier of affordable medicines five years  
after having complied with the TRIPS Agreement. The report compiles three  
main studies commissioned by UNDP by: Sudip Chaudhuri, Chan Park and K. M.  
Gopakumar. The studies demonstrate that developments in India have impacts  
well beyond its borders, given the reliance thus far of much of the global  
market, especially in developing countries and LDCs, on the supply of  
low-cost, quality Indian generic pharmaceutical products. The studies  
analyze the role of both the Indian pharmaceutical industry and the Indian  
legal system in building a post-TRIPS scenario that continue to be conducive  
to sourcing affordable medicines.

[http://content.undp.org/go/cms-service/download/publication/?version=live&id=3089934](http://content.undp.org/go/cms-service/download/publication/?version=live&id=3089934)  
[Fix link if broken; link leads to download of pdf document - DB]

2. The \*Good Practice Guide: Improving Access to Treatment by Utilizing Public  
Health Flexibilities in the WTO TRIPS Agreement \*has been prepared by the  
UNDP HIV/AIDS Group at the Bureau for Development Policy. In line with the  
objectives of the UNAIDS Strategy 2011 – 2015 “Getting to Zero”, the Good  
Practice Guide explains the impact of and connection between intellectual  
property rights and access to treatment. The Guide analyses many of the  
public health flexibilities in the TRIPS Agreement and provides examples  
where and how have they been used by national governments. This Guide can be  
used by legislators, policy makers and government officials in discussions  
on adopting or reforming relevant legislation, in the process of formulating  
national IPR and public health policies, as well as in negotiating WTO  
accession agreements, or bilateral trade agreements that contain reference  
to IPR obligations. As a tool, this Good Practice Guide provides the basics.

[http://content.undp.org/go/cms-service/download/publication/?version=live&id=3089678](http://content.undp.org/go/cms-service/download/publication/?version=live&id=3089678)  
[http://content.undp.org/go/cms-service/download/publication/?version=live&id=3089678](http://content.undp.org/go/cms-service/download/publication/?version=live&id=3089678)

Regards  
Tenu Avafia  
tavafia@gmail.com